Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    FLAURA
Previous Study | Return to List | Next Study

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02296125
Recruitment Status : Active, not recruiting
First Posted : November 20, 2014
Results First Posted : November 6, 2018
Last Update Posted : January 24, 2019
Sponsor:
Collaborator:
Parexel
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
To assess the efficacy and safety of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non Small Cell Lung Cancer

Condition or disease Intervention/treatment Phase
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer Drug: AZD9291 80 mg/40 mg + placebo Drug: Placebo Erlotinib 150/100mg Drug: Placebo Gefitinib 250 mg Drug: Erlotinib 150/100 mg Drug: Gefitinib 250 mg Drug: Placebo AZD9291 80 mg/ 40 mg Phase 3

Detailed Description:
This is a Phase III, double-blind, randomised study assessing the efficacy and safety of AZD9291 (80 mg orally, once daily) versus a standard of care (SoC) Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) (either gefitinib [250 mg orally, once daily] or erlotinib [150 mg orally, once daily]) in patients with locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) that is known to be EGFR sensitising mutation (EGFRm) positive, treatment-naïve and eligible for first-line treatment with an EGFR-TKI.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 674 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Double-blind, Randomised Study to Assess the Safety and Efficacy of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer.
Actual Study Start Date : December 3, 2014
Actual Primary Completion Date : June 19, 2017
Estimated Study Completion Date : June 28, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: AZD9291+ placebo
AZD9291 (80 mg or 40 mg orally, once daily) plus placebo Erlotinib (150mg or 100mg orally, once daily) or placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.
Drug: AZD9291 80 mg/40 mg + placebo

The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.

Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.


Drug: Placebo Erlotinib 150/100mg
The initial dose of Placebo Erlotinib 150 mg once daily can be reduced to Placebo 100 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Other Name: Placebo Tarceva 150/100 mg

Drug: Placebo Gefitinib 250 mg
The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Other Name: Placebo Iressa 250 mg

Active Comparator: Standard of Care + placebo AZD9291

Erlotinib (150 mg or 100 mg orally, once daily) or placebo Gefitinib (250 mg orally, once daily) plus placebo AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomisation schedule.

Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291).

Drug: Erlotinib 150/100 mg

The initial dose of Erlotinib 150mg once daily can be reduced to 10 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.

Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291).

Other Name: Tarceva 150/100 mg

Drug: Gefitinib 250 mg

The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.

Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291).

Other Name: Iressa 250mg

Drug: Placebo AZD9291 80 mg/ 40 mg
The initial dose of Placebo AZD9291 80 mg once daily can be reduced to Placebo AZD9291 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.




Primary Outcome Measures :
  1. Median Progression Free Survival (PFS) (Months) [ Time Frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomisation until progression (approximately 11.5 months) ]
    Progression-free survival was defined as the time from randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression and was used to assess the efficacy of single agent osimertinib compared with SoC EGFR-TKI therapy as measured by PFS.

  2. Percentage of Participants in Progression Free Survival at 6, 12, and 18 Months [ Time Frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomisation until progression (approximately 11.5 months) ]
    Progression-free survival was defined as the time from randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression and was used to assess the efficacy of single agent osimertinib compared with SoC EGFR-TKI therapy as measured by PFS.


Secondary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomisation until progression (approximately 11.5 months) ]
    ORR was defined as the number (%) of patients with measurable disease with at least 1 visit response of Complete response (CR) or Partial response (PR) and it was used to further assess the efficacy of osimertinib compared with SoC EGFR-TKI therapy

  2. Duration of Response (DoR) [ Time Frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks until objective disease progression (approximately 11.5 months) ]
    Duration of response was defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression and was used to further assess the efficacy of osimertinib compared with SoC EGFR-TKI therapy.

  3. Disease Control Rate (DCR) [ Time Frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks until objective disease progression (approximately 11.5 months) ]
    The DCR was defined as the percentage of participants who had a best overall response (BOR) of Complete response (CR), Partial response (PR) or Stable disease (SD) ≥6 weeks prior to any Progressive disease (PD) event and was used to further assess the efficacy of osimertinib compared with SoC EGFR-TKI therapy.

  4. Depth of Response [ Time Frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks until objective disease progression (approximately 11.5 months) ]
    The Depth of response was defined as the relative change in the sum of the longest diameters of Response Evaluation Criteria in Solid Tumors (RECIST) Target lesions (TLs) at the nadir, in the absence of new lesions (NLs) or progression of Non-target lesions (NTLs), compared to baseline and was used to further assess the efficacy of osimertinib compared with SoC EGFR-TKI therapy

  5. Overall Survival (OS)- Number of Participants With an Event [ Time Frame: From first dose to end of study or date of death from any cause, whichever comes first, assessed every 6 weeks (approximately 29 months) ]
    Overall survival was defined as the time from the date of randomisation until death from any cause and was used to further assess the efficacy of osimertinib compared with SoC EGFR-TKI therapy

  6. Plasma Concentrations of AZD9291 [ Time Frame: Blood samples collected from each participant at pre-dose, 0.5 to 2 hours, and 3 to 5 hours post-dose on Day 1 Cycle 1, and every other cycle thereafter up to and including Cycle 13 (approximately 9 months) ]
    To characterise the pharmacokinetics (PK) of osimertinib

  7. Plasma Concentrations of Metabolites AZ5104 [ Time Frame: Blood samples collected from each participant at pre-dose, 0.5 to 2 hours, and 3 to 5 hours post-dose on Day 1 Cycle 1, and every other cycle thereafter up to and including Cycle 13 (approximately 9 months) ]
    To characterise the pharmacokinetics (PK) of osimertinib metabolite AZ5104.

  8. Plasma Concentrations of Metabolite AZ7550 [ Time Frame: Blood samples collected from each participant at pre-dose, 0.5 to 2 hours, and 3 to 5 hours post-dose on Day 1 Cycle 1, and every other cycle thereafter up to and including Cycle 13 (approximately 9 months) ]
    To characterise the pharmacokinetics (PK) of osimertinib metabolite AZ7550.

  9. Participants Reported Outcome by Cancer Therapy Satisfaction Questionnaire 16 Items (CTSQ-16 Questionnaire) [ Time Frame: Questionnaire completed in cycle 2 and 3, prior to Week 6 scan (approximately 2 months) ]
    The CTSQ-16 was a 16-item questionnaire measuring 3 domains related to participant's satisfaction with cancer therapy: Expectations of therapy, Feelings about side effects, and Satisfaction with therapy. Scores ranged from 0 to 100 for each domain, with a higher score associated with the best outcome on each domain. The three domains of interest were separately analysed using an ANCOVA stratified by race (Asian versus Non-Asian) and mutation type (Ex19del versus L858R). The results of the analyses were presented in terms of mean together with standard deviation.

  10. Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ) Questionnaires Lung Cancer 13 (QLQ-LC13) [ Time Frame: Questionnaires completed at baseline, first 9 months, and at week 1, 2, 3, 4, 5, 6, 12, 18, 24, 30 and 36 ]
    The EORTC QLQ-LC13 was a lung-cancer-specific module comprising 13 questions to assess lung cancer symptoms (cough, haemoptysis, dyspnoea, and site-specific pain [pain in chest, pain in arm or shoulder, and pain in other parts); treatment related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia); and pain medication. Except for a multi-item scale for dyspnoea, all were single items. An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items. Higher scores on the global health status/QoL and functioning scales indicated better health status/QoL and better function. Higher scores on the symptoms scales indicated greater symptom burden. The results of the analyses were presented in terms of a least squares mean together with its associated 95% profile likelihood CI.

  11. Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Items (EORTC QLQ-C30) [ Time Frame: Questionnaires completed at baseline, first 9 months, and at week 6, 12, 18, 24, 30, and 36. ]
    The EORTC QLQ-C30 cancer-specific questionnaire consisted of 30 questions, which were combined to produce 5 functional scales (Physical, Role, Cognitive, Emotional, Social); 3 symptom scales (Fatigue, Pain, Nausea/Vomiting); 6 individual items (dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial difficulties); and a global measure of health status/QoL. An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items, the functional scales, and the global health status/QoL scale in the EORTC QLQ-C30. Higher scores on the global health status and functioning scales indicated better health status/function. Higher scores on the symptoms scales indicated greater symptom burden. The results of the analyses were presented in terms of a least squares mean together with its associated 95% profile likelihood CI.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female, aged at least 18 years.
  2. Pathologically confirmed adenocarcinoma of the lung.
  3. Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy.
  4. The tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R).
  5. Mandatory provision of an unstained, archived tumour tissue sample in a quantity sufficient to allow for central analysis of EGFR mutation status.
  6. Patients must be treatment-naïve for locally advanced or metastatic NSCLC and eligible to receive first-line treatment with gefitinib or erlotinib as selected by the participating centre. Prior adjuvant and neo-adjuvant therapy is permitted(chemotherapy, radiotherapy, investigational agents).
  7. Provision of informed consent prior to any study specific procedures, sampling, and analysis.
  8. World Health Organization Performance Status of 0 to 1 with no clinically significant deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks

Exclusion Criteria:

  1. Treatment with any of the following:

    • Prior treatment with any systemic anti-cancer therapy for locally advanced/metastatic NSCLC.
    • Prior treatment with an EGFR-TKI.
    • Major surgery within 4 weeks of the first dose of study drug.
    • Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.
    • Patients currently receiving medications or herbal supplements known to be potent inducers of cytochrome P450 (CYP) 3A4.
    • Alternative anti-cancer treatment
    • Treatment with an investigational drug within five half-lives of the compound or any of its related material.
  2. Any concurrent and/or other active malignancy that has required treatment within 2 years of first dose of study drug.
  3. Spinal cord compression, symptomatic and unstable brain metastases, except for those patients who have completed definitive therapy, are not on steroids, have a stable neurologic status for at least 2 weeks after completion of the definitive therapy and steroids.
  4. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).
  5. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of AZD9291.
  6. Any of the following cardiac criteria:

    • Mean resting corrected QT interval (QTc) >470 msec, obtained from 3 ECGs, using the screening clinic ECG machine-derived QTcF value.
    • Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG.
    • Any patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval.
  7. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
  8. Involvement in the planning and/or conduct of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02296125


  Hide Study Locations
Locations
Layout table for location information
United States, California
Research Site
Anaheim, California, United States, 92801
Research Site
Santa Rosa, California, United States, 95403
Research Site
West Hills, California, United States, 91307
United States, Florida
Research Site
Tampa, Florida, United States, 33612
United States, Georgia
Research Site
Atlanta, Georgia, United States, 30318
Research Site
Atlanta, Georgia, United States, 30322
Research Site
Marietta, Georgia, United States, 30060
United States, Kentucky
Research Site
Louisville, Kentucky, United States, 40202
United States, Maryland
Research Site
Bethesda, Maryland, United States, 20817
United States, Massachusetts
Research Site
Boston, Massachusetts, United States, 02215
United States, Minnesota
Research Site
Minneapolis, Minnesota, United States, 55407
United States, New Hampshire
Research Site
Lebanon, New Hampshire, United States, 3756
United States, North Carolina
Research Site
Salisbury, North Carolina, United States, 28144
United States, Vermont
Research Site
Burlington, Vermont, United States, 05401
Australia
Research Site
Camperdown, Australia, 2050
Research Site
Chermside, Australia, 4032
Research Site
Clayton, Australia, 3168
Research Site
Heidelberg, Australia, 3084
Research Site
Kogarah, Australia, 2217
Research Site
Nedlands, Australia, 6009
Research Site
Woolloongabba, Australia, 4102
Belgium
Research Site
Leuven, Belgium, 3000
Research Site
Liège, Belgium, 4000
Research Site
Roeselare, Belgium, 8800
Brazil
Research Site
Porto Alegre, Brazil, 90610-000
Bulgaria
Research Site
Sofia, Bulgaria, 1330
Canada, Alberta
Research Site
Edmonton, Alberta, Canada, T6G 1Z2
Canada, Ontario
Research Site
Hamilton, Ontario, Canada, L8V 5C2
Research Site
Ottawa, Ontario, Canada, K1H 8L6
Research Site
Toronto, Ontario, Canada, M4N 3M5
Research Site
Toronto, Ontario, Canada, M5G 1X5
Research Site
Toronto, Ontario, Canada, M5G 2M9
China
Research Site
Beijing, China, 100071
Research Site
Beijing, China, 100853
Research Site
Changchun, China, 130012
Research Site
Changchun, China, 130021
Research Site
Chongqing, China, 400037
Research Site
Chongqing, China, 400038
Research Site
Chongqing, China, 400042
Research Site
Fuzhou, China, 350025
Research Site
Guangzhou, China, 510080
Research Site
Hangzhou, China, 310022
Research Site
Nanjing, China, 210029
Research Site
Nanning, China, 530021
Research Site
Shanghai, China, 200433
Research Site
Shenyang, China, 110001
Research Site
Suzhou, China, 215006
Research Site
Wuhan, China, 430071
Research Site
Xi'an, China, 710038
Research Site
Xi'an, China, 710061
Research Site
Yangzhou, China, 225001
Research Site
Ürümqi, China, 830000
Czechia
Research Site
Ostrava, Czechia
France
Research Site
Caen, France, F-14033
Research Site
Creteil, France, 94010
Research Site
Lyon Cedex 08, France, 69373
Research Site
Nantes Cedex 02, France, 44202
Research Site
Toulon Naval, France, 83800
Research Site
Villejuif, France, 94805
Germany
Research Site
Bad Berka, Germany, 99437
Research Site
Berlin, Germany, 13125
Research Site
Gauting, Germany, 82131
Research Site
Halle, Germany, 06120
Research Site
Heidelberg, Germany, 69126
Research Site
Karlsruhe, Germany, 76137
Research Site
Lübeck, Germany, 23538
Research Site
München, Germany, 81925
Research Site
Villingen-Schwenningen, Germany, 78052
Hungary
Research Site
Farkasgyepü, Hungary, 8582
Research Site
Miskolc, Hungary, 3529
Research Site
Mátraháza, Hungary, H-3233
Research Site
Székesfehérvár, Hungary, 8000
Research Site
Tatabánya, Hungary, 2800
Research Site
Zalaegerszeg, Hungary, 8900
Israel
Research Site
Haifa, Israel, 31999
Research Site
Kfar-Saba, Israel, 4428164
Research Site
Petach Tikva, Israel, 49100
Research Site
Tel Hashomer, Israel, 52621
Italy
Research Site
Cremona, Italy, 26100
Research Site
Lecce, Italy, 73100
Research Site
Lecco, Italy, 23900
Research Site
Orbassano, Italy, 10043
Research Site
Parma, Italy, 43100
Research Site
Roma, Italy, 00144
Research Site
Sondrio, Italy, 23100
Research Site
Terni, Italy, 05100
Japan
Research Site
Chuo-ku, Japan, 104-0045
Research Site
Fukuoka-shi, Japan, 812-8582
Research Site
Hirakata-shi, Japan, 573-1191
Research Site
Kanazawa-shi, Japan, 920-8641
Research Site
Kashiwa, Japan, 277-8577
Research Site
Kobe-shi, Japan, 650-0047
Research Site
Matsuyama-shi, Japan, 791-0280
Research Site
Natori-shi, Japan, 981-1293
Research Site
Osaka-shi, Japan, 541-8567
Research Site
Osakasayama-shi, Japan, 589-8511
Research Site
Sagamihara-shi, Japan, 252-0375
Research Site
Sakai-shi, Japan, 591-8555
Research Site
Sendai-shi, Japan, 980-0873
Research Site
Sunto-gun, Japan, 411-8777
Research Site
Yokohama-shi, Japan, 232-0024
Research Site
Yokohama-shi, Japan, 236-0051
Research Site
Yokohama-shi, Japan, 240-8555
Research Site
Yokohama-shi, Japan, 241-8515
Korea, Republic of
Research Site
Cheongju-si, Korea, Republic of, 28644
Research Site
Incheon, Korea, Republic of, 405-760
Research Site
Seongnam-si, Korea, Republic of, 13620
Research Site
Seoul, Korea, Republic of, 02841
Research Site
Seoul, Korea, Republic of, 03722
Research Site
Seoul, Korea, Republic of, 06591
Research Site
Seoul, Korea, Republic of, 5030
Malaysia
Research Site
Kuala Lumpur, Malaysia, 59100
Research Site
Kuantan, Malaysia, 25100
Research Site
Kuching, Malaysia, 93586
Philippines
Research Site
Cebu, Philippines, 6000
Research Site
Manila, Philippines, 1000
Research Site
Quezon City, Philippines
Poland
Research Site
Brzozoów, Poland, 36-200
Research Site
Otwock, Poland, 05-400
Research Site
Poznań, Poland, 60-569
Research Site
Szczecin, Poland, 70-891
Research Site
Warszawa, Poland, 02-781
Portugal
Research Site
Amadora, Portugal, 2720-276
Research Site
Lisboa, Portugal, 1769-001
Research Site
Porto, Portugal, 4200-072
Research Site
Vila Nova de Gaia, Portugal, 4434-502
Romania
Research Site
Bucharest, Romania, 050098
Research Site
Bucuresti, Romania, 022328
Research Site
Craiova, Romania, 200347
Russian Federation
Research Site
Saint Petersburg, Russian Federation, 197022
Research Site
Saint Petersburg, Russian Federation, 197758
Research Site
Saint Petersburg, Russian Federation, 198255
Saudi Arabia
Research Site
Riyadh, Saudi Arabia, 11211
Spain
Research Site
Barcelona, Spain, 08041
Research Site
Barcelona, Spain, 08221
Research Site
Barcelona, Spain, 08907
Research Site
Coruña, Spain, 15006
Research Site
Lugo, Spain, 27003
Research Site
Lérida, Spain, 25198
Research Site
Madrid, Spain, 28040
Research Site
Málaga, Spain, 29010
Research Site
Sevilla, Spain, 41014
Research Site
Zaragoza, Spain, 50009
Sweden
Research Site
Linköping, Sweden, 581 85
Switzerland
Research Site
Luzern, Switzerland, 6000
Research Site
Winterthur, Switzerland, 8401
Research Site
Zürich, Switzerland, 8091
Taiwan
Research Site
Kaohsiung, Taiwan, 833
Research Site
Liou Ying Township, Taiwan, 73657
Research Site
Taichung, Taiwan, 402
Research Site
Tainan, Taiwan, 704
Research Site
Taoyuan City, Taiwan, 333
Thailand
Research Site
Bangkok, Thailand, 10330
Research Site
Bangkok, Thailand, 10400
Research Site
Bangkok, Thailand, 10700
Research Site
Chom Thon, Thailand, 50200
Research Site
Songkla, Thailand, 90110
Turkey
Research Site
Ankara, Turkey, 6500
Research Site
Istanbul, Turkey, 34069
Research Site
Izmir, Turkey, 35100
Ukraine
Research Site
Dnipropetrovsk, Ukraine, 49102
Research Site
Kryvyi Rih, Ukraine, 50048
Research Site
Lviv, Ukraine, 79031
Research Site
Sumy, Ukraine, 40022
United Kingdom
Research Site
Edinburgh, United Kingdom, EH4 2XU
Research Site
London, United Kingdom, NW1 2BU
Research Site
Maidstone, United Kingdom, ME16 9QQ
Research Site
Withington, United Kingdom, M20 4BX
Vietnam
Research Site
Hanoi, Vietnam
Research Site
Ho Chi Minh City, Vietnam, 70000
Sponsors and Collaborators
AstraZeneca
Parexel
  Study Documents (Full-Text)

Documents provided by AstraZeneca:
Study Protocol  [PDF] March 7, 2018
Statistical Analysis Plan  [PDF] February 28, 2017


Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02296125     History of Changes
Other Study ID Numbers: D5160C00007
2014-002694-11 ( EudraCT Number )
U1111-1160-2242 ( Other Grant/Funding Number: 112455 )
First Posted: November 20, 2014    Key Record Dates
Results First Posted: November 6, 2018
Last Update Posted: January 24, 2019
Last Verified: January 2019

Keywords provided by AstraZeneca:
Advanced Non-Small Cell Lung Cancer; EGFRm+; AZD9291; TKI; Phase III

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Erlotinib Hydrochloride
Gefitinib
Osimertinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action